DDIT3 and diffuse large B-cell lymphoma: In mice with diffuse large B-cell lymphoma (DLBCL) that were treated with CHOP and R-CHOP (addition of rituximab to standard CHOP therapy), the proportion of CD163+ macrophages were lower after both treatments, indicating a repolarization of M2-like macrophages to M1-like with these regimens (Figure 1) (63).